Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial

The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile. In all, 25 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Morant, R, Bernhard, J, Dietrich, D, Gillessen, S, Bonomo, M, Borner, M, Bauer, J, Cerny, T, Rochlitz, C, Wernli, M, Gschwend, A, Hanselmann, S, Hering, F, Schmid, H-P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409680/
https://www.ncbi.nlm.nih.gov/pubmed/15054447
http://dx.doi.org/10.1038/sj.bjc.6601673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409680/
https://www.ncbi.nlm.nih.gov/pubmed/15054447
http://dx.doi.org/10.1038/sj.bjc.6601673

Ejemplares similares